sel. CCR2 chemokine receptor antagonist

oral efficacy (25 mpk BID) in inflamm. models

from PK opt. of prior candidate

ACS Med. Chem. Lett., May 25, 2021

Bristol Myers Squibb, Princeton, NJ

The BMS CCR2 inhibitor, BMS-753426, is a potent, oral follow-up molecule to prior clinical candidate, BMS-741672. A small change from a methyl and isopropyl-substituted tertiary amine to a t-butyl secondary amine…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.